Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Report 2026

Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Overview

• Endoscopic Retrograde Cholangiopancreatography (ERCP) market size has reached to $1.86 billion in 2025 • Expected to grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Increasing Prevalence Of Gastrointestinal Conditions Driving The Growth Of The Market • Market Trend: Advancing ERCP Procedures with Innovative Cholangioscope Technologies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?

Endoscopic retrograde cholangiopancreatography (ERCP) is a medical procedure that combines endoscopy and X-ray imaging to diagnose and treat conditions affecting the bile ducts, gallbladder, and pancreas. It involves guiding a flexible, lighted tube (endoscope) through the mouth to the small intestine, allowing physicians to examine these organs and address issues such as blockages or stones. The main products in endoscopic retrograde cholangiopancreatography (ERCP) are endoscopes, endotherapy devices, visualization systems, and energy devices. Endoscopes are flexible tubes equipped with a light and camera, allowing doctors to view the inside of the body, particularly the digestive tract, during procedures like ERCP. The various disease indications include gastroesophageal reflux disease (GERD), gastrointestinal cancer, barrett's esophagus, bile duct diseases, peptic ulcer disease, crohn's disease, intestinal pseudo-obstruction, ogilvie syndrome, and others, and several applications including biliary sphincterotomy, biliary dilatation, biliary stenting, pancreatic sphincterotomy, pancreatic duct dilatation, and pancreatic duct stenting. The different end users encompass hospitals and clinics, ambulatory surgery centers, and others.

What Is The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Growth Forecast?

The endoscopic retrograde cholangiopancreatography (ercp) market size is expected to see strong growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to advanced endoscopic training, early pancreatic diagnosis, therapeutic procedure growth, hospital infrastructure upgrades, minimally invasive care demand. Major trends in the forecast period include rising incidence of biliary disorders, increased use of therapeutic endoscopy, growth in minimally invasive GI procedures, expansion of advanced endoscopy units, focus on early diagnosis of pancreatic diseases.

Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Segmentation

1) By Product: Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices 2) By Application: Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, Pancreatic Sphincterotomy, Pancreatic Duct Dilatation, Pancreatic Duct Stentin 3) By End User: Hospitals And Clinics, Ambulatory Surgery Centers, Other End Users Subsegments: 1) By Endoscopes: Flexible Endoscopes, Semi-Rigid Endoscopes, High-Resolution Endoscopes 2) By Endotherapy Devices: Stone Extraction Devices, Balloon Dilatation Catheters, Stents, Biopsy Forceps 3) By Visualization Systems: High-Definition Visualization Systems, Endoscopic Imaging Systems, Video Endoscopes 4) By Energy Devices: Electrosurgical Devices, Laser Devices, Argon Plasma Coagulation Systems

What Is The Driver Of The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?

The increasing prevalence of gastrointestinal conditions is expected to propel the growth of the endoscopic retrograde cholangiopancreatography (ERCP) market going forward. Gastrointestinal conditions refer to a broad range of disorders or diseases that affect the gastrointestinal (GI) tract, which includes the mouth, esophagus, stomach, small intestine, large intestine (colon), rectum, and anus, as well as accessory organs like the liver, gallbladder, and pancreas. The increasing prevalence of gastrointestinal conditions can be attributed to several factors, including dietary changes, an aging population, antibiotic use, lifestyle factors, and environmental influences. ERCP helps treat patients with gastrointestinal conditions by providing a minimally invasive method to diagnose and treat issues within the bile and pancreatic ducts, such as gallstones, strictures, tumors, or infections. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, it is estimated that there are about 26,890 new cases of stomach cancer in the United States with around 10,880 deaths expected from this type of cancer. Therefore, the increasing prevalence of gastrointestinal conditions is driving the growth of the endoscopic retrograde cholangiopancreatography (ERCP) industry.

Key Players In The Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market

Major companies operating in the endoscopic retrograde cholangiopancreatography (ercp) market are Medtronic plc, Fujifilm Holdings Corporation, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Ottomed Endoscopy, W. L. Gore & Associates Inc., Streis plc, Cook Group, KARL STORZ SE & Co. KG, CONMED Corporation, PENTAX Medical Inc., AMBU Inc., Samsung Medison Co. Ltd., Medi-Globe GmbH, Telemed System Inc., Micro-Tech Endoscopy Inc., Hobbs Medical Inc., Shaili Endoscopy Pvt. Ltd.

Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Trends and Insights

Major companies operating in the ERCP market are focusing on developing innovative technologies, such as the cholangioscope direct visualisation system, to provide advanced, high-resolution direct visualisation of the bile and pancreatic ducts. The cholangioscope direct visualization system is a medical device that provides advanced, high-resolution imaging of the bile and pancreatic ducts during ERCP procedures. For instance, in July 2024, Penlon Limited, a UK-based medical device company, launched the VedVision Cholangioscope Direct Visualisation System, an advanced medical device designed for high-resolution, direct visualization of the bile and pancreatic ducts, enhancing diagnosis and therapeutic intervention during ERCP procedures. It features a 2 mm accessory channel and a dedicated guidewire channel for secure access, supported by a full range of accessories such as biopsy forceps, stone extraction baskets, cytology brushes, and polypectomy snares.

What Are Latest Mergers And Acquisitions In The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?

In April 2025, Medtronic Plc, a US-based medical technology company that provides devices used for Endoscopic Retrograde Cholangiopancreatography (ERCP) procedures, partnered with Dragonfly Endoscopy Inc. to distribute the Dragonfly Pancreaticobiliary System in the US, combining their expertise to enhance precision, visualization, and safety in ERCP procedures. With this partnership, Medtronic and Dragonfly Endoscopy aim to leverage their respective expertise in medical devices, combining Medtronic’s extensive commercialization and clinical support network with Dragonfly Endoscopy’s advanced pancreaticobiliary imaging and intervention technology to provide gastroenterologists and surgeons with a comprehensive solution that enhances visualization, precision, and safety in endoscopic retrograde cholangiopancreatography (ERCP) procedures, ultimately improving patient outcomes. Dragonfly Endoscopy Inc. is a US-based company that develops pancreaticobiliary endoscopy systems, for US distribution of the Dragonfly Pancreaticobiliary System.

Regional Outlook

North America was the largest region in the endoscopic retrograde cholangiopancreatography (ERCP) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?

The endoscopic retrograde cholangiopancreatography (ERCP) market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, post-operative, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The endoscopic retrograde cholangiopancreatography (ERCP) market also includes sales of biliary stents, guidewires, and catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Report 2026?

The endoscopic retrograde cholangiopancreatography (ercp) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the endoscopic retrograde cholangiopancreatography (ercp) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.